Induction of histone acetylation and inhibition of growth by phenyl alkanoic acid and structurally related molecules

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 1, 2004, Pages 57-63

  Lea, Michael A ^a   Shareef, Asif ^b   Sura, Monali ^a   DesBordes, Charles ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Histone deacetylase; Phenyl alkanoic acids

Indexed keywords

10 PHENYLDECANOATE; 4 CYCLOHEXYLBUTYRATE; 4 PHENYLBUTYRIC ACID; 5 PHENYLPENTA 2,4 DIENOATE; 5 PHENYLPENTANOATE; 6 PHENYLHEXANOATE; 7 PHENYLHEPTA 2,4,6 TRIENOATE; 7 PHENYLHEPTANOATE; 8 PHENYLOCTANOATE; ANTINEOPLASTIC AGENT; CARBON; CG 1255; CG 1520; HISTONE; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE S PHASE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG POTENCY; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; STRUCTURE ACTIVITY RELATION;

ACETYLATION; ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE; COLONIC NEOPLASMS; HISTONES; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MALE; MICE; PHENYLBUTYRATES; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042803851     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0782-5     Document Type: Article

References (29)

1. Boffa LC, Vidali G, Mann RS, Allfrey VG (1978) Suppression of histone deacetylation in vivo and in vitro by sodium butyrate J Biol Chem 253:3364
2. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG, Simons JW (1996) Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Res 2:379
3. Chang T-H, Szabo E (2002) Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-γ and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 8:1206
4. Clarke KO, Ludeman SM, Springer JB, Colvin OM, Lea MA, Harrison LE, (2002) Exposure to a deuterated analogue of phenylbutyrate retards S phase progression in HT-29 colon cancer cells. J Pharm Sci 91:1054
5. Fajas L, Egler V, Reiter R, Hansen J, Kristiansen K, Debril MB, Miard S, Auwerx J (2002) The retinoblastoma-histone deacetylase 3 complex inhibits PPARγ and adipocyte differentiation. Dev Cell 3:903
6. Feinman R, Clarke KO, Harrison LE (2002) Phenylbutyrate-induced apoptosis is associated with inactivation of NF-κB in HT-29 colon cancer cells. Cancer Chemother Pharmacol 49:27
7. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292
8. Gore SD, Carducci MA (2000) Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Exp Opin Invest Drugs 9:2923
9. Gore SD, Weng L-J, Figg WD, Zhai SZ, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks, K, Zabelena Y, Miller CB (2002) Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8:963
10. Houseknecht KL, Cole BM, Steele PJ (2002) Peroxisome proliferator- activated receptor gamma (PPARγ) and its ligands: a review. Domestic Animal Endocrinol 22:1
11. Hruban Z, Morris HP, Mochizuki Y, Meranze DR, Slesers A (1971) Light microscopic observations of Morris hepatomas. Cancer Res 31:752
12. Jung M (2001) Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 8:1505
13. Krämer OH, Göttlicher M, Heinzel T (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12:294
14. Lea MA, Randolph VM (1998) Induction of reporter gene expression by inhibitors of histone deacetylase. Anticancer Res 18:2717
15. Lea MA, Tulsyan N (1995) Discordant effects of butyrate analogues on erythroleukemia cell proliferation and histone deacetylase. Anticancer Res 15:879
16. Lea MA, Randolph VM, Hodge SK (1999) Induction of histone acetylation and growth regulation in erythroleukemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res 19:1971
17. Lea MA, Rasheed M, Randolph VM, Khan F, Shareef A, desBordes C (2002) Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr Cancer 43:90
18. Lea MA, Shareef A, desBordes C (2003) Actions other than inhibition of histone deacetylase may be more important for growth inhibition by some phenyl alkanoic and phenyl alkenoic acids. Proc Am Assoc Cancer Res 44 (2nd edn), 1315
19. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194
20. Melchior SW, Brown LG, Figg WD, Quinn JA, Santucci RA, Brunner J, Thüroff JW, Lange PH, Vessella RL (1999) Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int J Oncol 14:501
21. Morris HP, Meranze DR (1974) Induction and some characteristics of "minimal deviation" and other transplantable rat hepatomas. Recent Results Cancer Res 44:102
22. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA (2001) Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61:1477
23. Pineau T, Hudgins WR, Liu L, Chen L-C, Sher T, Gonzalez FJ, Samid D (1996) Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 52:659
24. Reeves R, Candido EPM (1978) Turnover of histone acetyl groups in cultured cells is inhibited by sodium butyrate. FEBS Lett 91:117
25. Rosen ED, Spiegelman BM (2001) PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731
26. Samid D, Wells M, Greene ME, Shen W, Palmer CAN, Thibault A (2000) Peroxisome proliferator-activated receptor γ as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res 6:933
27. Sealy L, Chalkley R (1978) The effect of sodium butyrate on histone modification. Cell 14:115
28. Warrell RP, He L-Z, Richon V, Calleja E, Pandolfi PP (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621
29. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48:S20